Rigorous pre-clinical evaluation of topical microbicides to prevent transmission of human immunodeficiency virus
Open Access
- 14 April 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 51 (5) , 1099-1102
- https://doi.org/10.1093/jac/dkg214
Abstract
With over 40 million people world-wide living with human immunodeficiency virus (HIV) and an estimated 16 000 new infections each day,1 there is an urgent need to identify safe and effective topical microbicides. Microbicides are products designed to prevent acquisition or transmission of HIV and other sexually transmitted infections (STIs) when applied in the vagina or rectum. Microbicides offer the potential to dramatically reduce rates of transmission of STIs, including HIV. Mathematical modelling predicts that over 3 years, 2.5 million infections could be averted if a microbicide that is 60% effective against HIV were used by 20% of women in half of all sex acts that do not involve a condom.2Keywords
This publication has 0 references indexed in Scilit: